Advertisement

Plasma Activated Medium

  • Hiromasa Tanaka
  • Masaru Hori
Chapter

Abstract

Plasma activated medium is a novel therapeutic agent that has anti-tumor effects on a wide variety of cancers. The application of plasma chemistry and molecular cell biology is gradually revealing the nature of plasma-induced physiological outputs. General factors, such as hydrogen peroxide and nitrite ions, are produced through interactions between plasma and air or water. Specific factors that are produced through interactions between plasma and solutes are also important for physiological outputs, such as apoptosis and proliferation. The intracellular molecular mechanisms underlying the anti-tumor effects of plasma activated medium are gradually being elucidated, including the key impacts of intracellular reactive oxygen species on survival and proliferating signaling networks. Animal studies have been conducted to investigate the potential clinical applications of plasma activated medium, including in particular, the treatment of cancer. In the future, many types of plasma activated medium will be developed for a broad range of medical applications.

Keywords

Plasma activated medium (PAM) Plasma medicine Plasma cancer treatment Apoptosis Reactive oxygen species (ROS) 

References

  1. 1.
    von Woedtke T, Metelmann HR, Weltmann KD. Clinical plasma medicine: state and perspectives of in vivo application of cold atmospheric plasma. Contrib Plasma Phys. 2014;54:104–17.CrossRefGoogle Scholar
  2. 2.
    Weltmann KD, Kindel E, Brandenburg R, Meyer C, Bussiahn R, Wilke C, von Woedtke T. Atmospheric pressure plasma jet for medical therapy: plasma parameters and risk estimation. Contrib Plasma Phys. 2009;49:631–40.CrossRefGoogle Scholar
  3. 3.
    Fridman G, Friedman G, Gutsol A, Shekhter AB, Vasilets VN, Fridman A. Applied plasma medicine. Plasma Process Polym. 2008;5:503–33.CrossRefGoogle Scholar
  4. 4.
    Laroussi M. From killing bacteria to destroying cancer cells: 20 years of plasma medicine. Plasma Process Polym. 2014;11:1138–41.CrossRefGoogle Scholar
  5. 5.
    Kong MG, Kroesen G, Morfill G, Nosenko T, Shimizu T, van Dijk J, Zimmermann JL. Plasma medicine: an introductory review. New J Phys. 2009;11:115012.CrossRefGoogle Scholar
  6. 6.
    Isbary G, Shimizu T, Li YF, Stolz W, Thomas HM, Morfill GE, Zimmermann JL. Cold atmospheric plasma devices for medical issues. Expert Rev Med Devices. 2013;10:367–77.CrossRefGoogle Scholar
  7. 7.
    Tanaka H, Mizuno M, Ishikawa K, Takeda K, Nakamura K, Utsumi F, Kajiyama H, Kano H, Okazaki Y, Toyokuni S, Maruyama S, Kikkawa F, Hori M. Plasma medical science for cancer therapy: toward cancer therapy using nonthermal atmospheric pressure plasma. IEEE Trans Plasma Sci. 2014;42:3760–4.CrossRefGoogle Scholar
  8. 8.
    Miller V, Lin A, Fridman G, Dobrynin D, Fridman A. Plasma stimulation of migration of macrophages. Plasma Process Polym. 2014;11:1193–7.CrossRefGoogle Scholar
  9. 9.
    Miller V, Lin A, Kako F, Gabunia K, Kelemen S, Brettschneider J, Fridman G, Fridman A, Autieri M. Microsecond-pulsed dielectric barrier discharge plasma stimulation of tissue macrophages for treatment of peripheral vascular disease. Phys Plasmas. 2015;22:122005.CrossRefGoogle Scholar
  10. 10.
    Lin A, Truong B, Pappas A, Kirifides L, Oubarri A, Chen SY, Lin SJ, Dobrynin D, Fridman G, Fridman A, Sang N, Miller V. Uniform nanosecond pulsed dielectric barrier discharge plasma enhances anti-tumor effects by induction of immunogenic cell death in tumors and stimulation of macrophages. Plasma Process Polym. 2015;12:1392–9.CrossRefGoogle Scholar
  11. 11.
    Miller V, Lin A, Fridman A. Why target immune cells for plasma treatment of cancer. Plasma Chem Plasma Process. 2016;36:259–68.CrossRefGoogle Scholar
  12. 12.
    Tanaka H, Mizuno M, Ishikawa K, Nakamura K, Kajiyama H, Kano H, Kikkawa F, Hori M. Plasma-activated medium selectively kills glioblastoma brain tumor cells by down-regulating a survival signaling molecule, AKT kinase, plasma. Medicine. 2013;1:265–77.Google Scholar
  13. 13.
    Utsumi F, Kajiyama H, Nakamura K, Tanaka H, Mizuno M, Ishikawa K, Kondo H, Kano H, Hori M, Kikkawa F. Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo. PLoS One. 2013;8:e81576.CrossRefGoogle Scholar
  14. 14.
    Tanaka H, Mizuno M, Ishikawa K, Nakamura K, Utsumi F, Kajiyama H, Kano H, Maruyama S, Kikkawa F, Hori M. Cell survival and proliferation signaling pathways are downregulated by plasma-activated medium in glioblastoma brain tumor cells, plasma. Medicine. 2014;2:207–20.Google Scholar
  15. 15.
    Torii K, Yamada S, Nakamura K, Tanaka H, Kajiyama H, Tanahashi K, Iwata N, Kanda M, Kobayashi D, Tanaka C, Fujii T, Nakayama G, Koike M, Sugimoto H, Nomoto S, Natsume A, Fujiwara M, Mizuno M, Hori M, Saya H, Kodera Y. Effectiveness of plasma treatment on gastric cancer cells. Gastric Cancer. 2014;18:635–43.CrossRefGoogle Scholar
  16. 16.
    Hattori N, Yamada S, Torii K, Takeda S, Nakamura K, Tanaka H, Kajiyama H, Kanda M, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Mizuno M, Hori M, Kodera Y. Effectiveness of plasma treatment on pancreatic cancer cells. Int J Oncol. 2015;47:1655–62.CrossRefGoogle Scholar
  17. 17.
    Tanaka H, Mizuno M, Ishikawa K, Kondo H, Takeda K, Hashizume H, Nakamura K, Utsumi F, Kajiyama H, Kano H, Okazaki Y, Toyokuni S, Akiyama S, Maruyama S, Yamada S, Kodera Y, Kaneko H, Terasaki H, Hara H, Adachi T, Iida M, Yajima I, Kato M, Kikkawa F, Hori M. Plasma with high electron density and plasma-activated medium for cancer treatment. Clin Plasma Med. 2015;3:72–6.CrossRefGoogle Scholar
  18. 18.
    Tanaka H, Mizuno M, Toyokuni S, Maruyama S, Kodera Y, Terasaki H, Adachi T, Kato M, Kikkawa F, Hori M. Cancer therapy using non-thermal atmospheric pressure plasma with ultra-high electron density. Phys Plasmas. 2015;22:122003.CrossRefGoogle Scholar
  19. 19.
    Tanaka H, Nakamura K, Mizuno M, Ishikawa K, Takeda K, Kajiyama H, Utsumi F, Kikkawa F, Hori M. Non-thermal atmospheric pressure plasma activates lactate in Ringer’s solution for anti-tumor effects. Sci Rep. 2016;6:36282.CrossRefGoogle Scholar
  20. 20.
    Tanaka H, Ishikawa K, Mizuno M, Toyokuni S, Kajiyama H, Kikkawa F, Metelmann HR, Hori M. State of the art in medical applications using non-thermal atmospheric pressure plasma. Rev Mod Plasma Phys. 2017;1:3.CrossRefGoogle Scholar
  21. 21.
    Utsumi F, Kajiyama H, Nakamura K, Tanaka H, Hori M, Kikkawa F. Selective cytotoxicity of indirect nonequilibrium atmospheric pressure plasma against ovarian clear-cell carcinoma. Springerplus. 2014;3:398.CrossRefGoogle Scholar
  22. 22.
    Takeda S, Yamada S, Hattori N, Nakamura K, Tanaka H, Kajiyama H, Kanda M, Kobayashi D, Tanaka C, Fujii T, Fujiwara M, Mizuno M, Hori M, Kodera Y. Intraperitoneal administration of plasma-activated medium: proposal of a novel treatment option for peritoneal metastasis from gastric cancer. Ann Surg Oncol. 2017;24:1188–94.CrossRefGoogle Scholar
  23. 23.
    Adachi T, Tanaka H, Nonomura S, Hara H, Kondo SI, Hori M. Plasma-activated medium induces A549 cell injury via a spiral apoptotic cascade involving the mitochondrial-nuclear network. Free Radic Biol Med. 2014;79C:28–44.Google Scholar
  24. 24.
    Hara H, Taniguchi M, Kobayashi M, Kamiya T, Adachi T. Plasma-activated medium-induced intracellular zinc liberation causes death of SH-SY5Y cells. Arch Biochem Biophys. 2015;584:51–60.CrossRefGoogle Scholar
  25. 25.
    Mohades S, Laroussi M, Sears J, Barekzi N, Razavi H. Evaluation of the effects of a plasma activated medium on cancer cells. Phys Plasmas. 2015;22:122001.CrossRefGoogle Scholar
  26. 26.
    Ohashi N, Kodera Y, Nakanishi H, Yokoyama H, Fujiwara M, Koike M, Hibi K, Nakao A, Tatematsu M. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol. 2005;27:637–44.PubMedGoogle Scholar
  27. 27.
    Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27:5497–510.CrossRefGoogle Scholar
  28. 28.
    Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26:3279–90.CrossRefGoogle Scholar
  29. 29.
    Ye F, Kaneko H, Nagasaka Y, Ijima R, Nakamura K, Nagaya M, Takayama K, Kajiyama H, Senga T, Tanaka H, Mizuno M, Kikkawa F, Hori M, Terasaki H. Plasma-activated medium suppresses choroidal neovascularization in mice: a new therapeutic concept for age-related macular degeneration. Sci Rep. 2015;5:7705.CrossRefGoogle Scholar
  30. 30.
    Matsumoto R, Shimizu K, Nagashima T, Tanaka H, Mizuno M, Kikkawa F, Hori M, Honda H. Plasma-activated medium selectively eliminates undifferentiated human induced pluripotent stem cells. Regen Ther. 2016;5:55–63.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Nagoya UniversityNagoyaJapan

Personalised recommendations